Moderna's COVID-19 vaccine may work better in the elderly than competitors’

New Phase I data suggest Moderna’s COVID-19 vaccine maintains its immunogenicity in elderly individuals better than two other leading vaccines. Assuming neutralizing antibodies are key determinants of protection, and that the early results hold up, that could mean mRNA-1273 will do a better job of protecting the high-risk population.

The weakening immune systems in older individuals have been a concern for vaccine developers, given that immune function is needed for vaccines induce protection against pathogens. ...